Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 02:07:52 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.065 USD 0.00% Intraday chart for Aridis Pharmaceuticals, Inc. +8.33% -7.28%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Capitalization 1 89.88 39.66 61.1 32.75 29.39 3.115 3.115
Enterprise Value (EV) 1 89.88 39.66 61.1 32.75 29.39 3.115 3.115
P/E ratio -3.83 x -1.27 x -2.49 x -0.61 x -0.73 x 0.93 x -0.72 x
Yield - - - - - - -
Capitalization / Revenue 32.6 x 38.8 x 61.1 x 21.3 x 9.51 x 0.15 x 0.41 x
EV / Revenue 32.6 x 38.8 x 61.1 x 21.3 x 9.51 x 0.15 x 0.41 x
EV / EBITDA - -1,379,506 x - - - - -
EV / FCF -3,602,764 x -4,759,320 x - - - - -
FCF Yield -0% -0% - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 8,105 8,912 10,066 14,054 24,909 47,929 47,929
Reference price 2 11.09 4.450 6.070 2.330 1.180 0.0650 0.0650
Announcement Date 3/28/19 4/8/20 3/30/21 4/1/22 5/22/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net sales 1 2.757 1.022 1 1.535 3.091 21.4 7.6
EBITDA - -28.75 - - - - -
EBIT 1 -24.12 -29.09 -22.4 -43.71 -29.99 5.6 -4.3
Operating Margin -874.76% -2,846.09% -2,240.1% -2,847.62% -970.33% 26.17% -56.58%
Earnings before Tax (EBT) 1 -22.1 -29.68 -22.33 -43.19 -30.37 4.3 -4.3
Net income 1 -23.46 -29.68 -22.33 -47.32 -30.37 4.3 -4.3
Net margin -851% -2,904.21% -2,233.3% -3,082.74% -982.56% 20.09% -56.58%
EPS 2 -2.894 -3.510 -2.440 -3.850 -1.620 0.0700 -0.0900
Free Cash Flow -24.95 -8.333 - - - - -
FCF margin -904.9% -815.36% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/28/19 4/8/20 3/30/21 4/1/22 5/22/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 0.033 0.515 0.57 1.187 0.292 0.399 1.213 - - 0.417 0.3
EBITDA - - - - - - - - - - -
EBIT 1 -6.234 -21.03 -9.969 -7.424 -7.737 -7.412 -7.42 - - -0.869 -1
Operating Margin -18,890.91% -4,082.72% -1,748.95% -625.44% -2,649.66% -1,857.64% -611.71% - - -208.39% -333.33%
Earnings before Tax (EBT) 1 -5.49 -21 -10.23 -7.766 -7.979 -8.239 -10.5 - - -0.083 -1
Net income 1 -5.49 -24.14 -13.37 -7.766 -7.979 -8.239 -10.5 - 12.14 -0.083 -1
Net margin -16,636.36% -4,687.96% -2,345.26% -654.25% -2,732.53% -2,064.91% -865.21% - - -19.9% -333.33%
EPS 2 -0.4900 -1.940 -0.9200 -0.4400 -0.4500 -0.4700 -0.5000 -0.2200 0.3300 - -0.0200
Dividend per Share - - - - - - - - - - -
Announcement Date 8/12/21 11/10/21 4/1/22 5/16/22 8/16/22 11/21/22 5/22/23 6/9/23 9/14/23 11/3/23 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -24.9 -8.33 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 0.68 0.17 0.37 - - - -
Capex / Sales 24.56% 17.03% 36.7% - - - -
Announcement Date 3/28/19 4/8/20 3/30/21 4/1/22 5/22/23 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Aridis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.065 USD
Average target price
2 USD
Spread / Average Target
+2,976.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARIDIS PHARMACEUTICALS, INC. Stock Aridis Pharmaceuticals, Inc.
-7.28% 3.12M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. Financials Aridis Pharmaceuticals, Inc.